Cristina Helena dos Reis Serra
University of São Paulo
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cristina Helena dos Reis Serra.
European Journal of Pharmaceutical Sciences | 2013
Juliana Mazza Reis; André Bersani Dezani; Thaisa Marinho Pereira; A. Avdeef; Cristina Helena dos Reis Serra
In order to reach the bloodstream and thus the target receptor, an orally-administered drug must first cross the intestinal barrier, which can occur via a paracellular, passive transcellular, or carrier-mediated uptake and/or efflux process (active or concentration gradient-driven). Our work aimed to explore the transport mechanism of the antiretroviral lamivudine (deoxycytidine nucleoside analogue), using a three-part strategy: in vitro, an ex vivo and an in situ method, represented by PAMPA, rat jejunum patches and rat Single Pass Intestinal Perfusion (SPIP), respectively. The determined permeability coefficients were compared with those from a published Caco-2 and MDCK study. Computational prediction of human jejunal permeability was explored, using various non-human permeability coefficients as descriptors. The ex vivo technique was performed in Franz-type diffusion cells, mounted with male Wistar rat jejunum segment patches. PAMPA was performed with an acceptor solution simulating the binding of serum proteins, an artificial membrane impregnated with egg lecithin/cholesterol and a gradient of pH between donor and acceptor solutions. The SPIP was conducted by proximal jejunum cannulation and drug perfusion in a constant flow rate of 0.2 mL/min. The outcomes of our studies showed the following predicted pattern for lamivudine effective jejunal permeability: P(eff)(exvivoA>B)>P(eff)(SPIP)>P(eff)(exvivo B>A)>P(eff)(Caco-2)≈P(eff)(MDCK)≈P(eff)(PAMPA), strongly suggesting that this compound has carrier-mediated uptake as its dominant transport mechanism. Notwithstanding, Caco-2 cells may indicate an under-expression of uptake transporters and possibly an over-expression efflux transporters, compared to that found in the rat jejunum.
Revista Brasileira De Ciencias Farmaceuticas | 2007
Cristina Helena dos Reis Serra; Sílvia Storpirtis
O presente estudo reporta os resultados comparativos obtidos atraves da avaliacao da cinetica e da eficiencia de dissolucao da cefalexina a partir de dois lotes (1 e 2) de diferentes produtos contendo tal farmaco disponiveis no mercado brasileiro (A e B) sob a forma de comprimidos de liberacao convencional. Os perfis de dissolucao foram determinados utilizando as seguintes condicoes: aparato 1 (cesta, 40 mesh); 100 rpm; 900 mL de agua destilada mantida a 37±0,5 °C. Amostras coletadas em: 5, 7, 10, 15, 20, 30, 40, 50 e 60 minutos e a concentracao de cefalexina foi determinada por espectrofotometria UV (262 nm). A partir dos perfis de dissolucao determinou-se: modelo matematico de liberacao da cefalexina (primeira-ordem); porcentagem de cefalexina dissolvida em 30 minutos (Q30); constante da velocidade de dissolucao (k); meia-vida de dissolucao (t50%); eficiencia de dissolucao (ED%). Os valores Q30 obtidos indicaram que os produtos A2 e B2 se apresentaram de acordo com as especificacoes farmacopeicas. A comparacao entre os perfis indicou diferencas estatisticamente significativa entre os produtos A2 e B1 (analise comparativa dos parâmetros cineticos), A1 e B2 (analise comparativa pelos fatores de diferenca - f1 e similaridade - f2) e B1 e B2 (analise comparativa dos parâmetros cineticos e da ED%).
Pharmacology | 2012
Josilene Chaves Ruela Corrêa; Deirdre M. D'Arcy; Cristina Helena dos Reis Serra; Hérida Regina Nunes Salgado
Darunavir is a synthetic nonpeptidic protease inhibitor which has been shown to be extremely potent against wild-type HIV as well as a large panel of PI-resistant clinical isolates and shows a high genetic barrier to the development of antiretroviral resistance. The treatment of HIV/AIDS requires combinations of multiple antiretroviral drugs. In addition, patients frequently need to coadminister other medications for reasons including the prevention or treatment of opportunistic infections, treatment of concomitant illnesses and management of antiretroviral side effects. Drug interactions have been observed between darunavir and other drugs. New and more comprehensive drug interaction studies will be required since the increase in life expectancy of patients often brings new comorbidities and the concomitant use of different drugs. This paper discusses the impact of the use of darunavir in the treatment of HIV-infected patients, its pharmacological and physical-chemical properties, its drug interactions, and challenges that remain in order to ensure safety and compliance of treatment.
Pharmaceutical Research | 2011
Luciana A. Corá; Madileine F. Américo; Ricardo Brandt de Oliveira; Cristina Helena dos Reis Serra; Oswaldo Baffa; Raul Cesar Evangelista; Giselle F. Oliveira; Jose Ricardo Aruda Miranda
ABSTRACTBiomagnetic methods have been designed for a wide range of applications. Recently, such methods have been proposed as alternatives to scintigraphy for evaluating of a number of pharmaceutical processes in vitro as well as under the influence of gastrointestinal physiological parameters. In this review, physical characterization as well as the most recent applications of Superconducting Quantum Interference Device (SQUID), Anisotropic Magnetoresistive (AMR) and AC Biosusceptometry (ACB) in the pharmaceutical research will be explored. Moreover, their current status and how these technologies can be employed to improve the knowledge about the impact of gastrointestinal physiology on drug delivery in association with pharmacokinetic outcomes, termed pharmacomagnetography, will be presented.
International Journal of Pharmaceutics | 2010
Samanta Mourão; Cristiane B. da Silva; Tania M.B. Bresolin; Cristina Helena dos Reis Serra; Valentina Porta
Sodium diclofenac (SD) release from dosage forms has been studied under different conditions. However, no dissolution method that is discriminatory enough to reflect slight changes in formulation or manufacturing process, and which could be effectively correlated with the biological properties of the dosage form, has been reported. This study sought to develop three different formulae of SD-containing matrix tablets and to determine the effect of agitation speed in its dissolution profiles. F1, F2 and F3 formulations were developed using hypromellose (10, 20 and 30%, respectively for F1, F2 and F3) and other conventional excipients. Dissolution tests were carried out in phosphate buffer pH 6.8 at 37 degrees C using apparatus II at 50, 75 or 100 rpm. Dissolution efficiency (DE), T(50) and T(90) were determined and plotted as functions of the variables agitation speed and hypromellose concentration. Regarding DE, F2 showed more sensitivity to variations in agitation speed than F1 and F3. Increasing hypromellose concentration reduced DE values, independent of agitation speed. Analysis of T(50) and T(90) suggests that F1 is less sensitive to variations in agitation speed than F2 and F3. Most discriminatory dissolution conditions were observed at 50 rpm. Results suggest that the comparison of dissolution performance of SD matrix tablets should take into account polymer concentration and agitation conditions.
Journal of Pharmacological and Toxicological Methods | 2013
André Bersani Dezani; Thaisa Marinho Pereira; Arthur Massabki Caffaro; Juliana Mazza Reis; Cristina Helena dos Reis Serra
INTRODUCTION The major processes that control the absorption of orally administered drugs are dissolution and gastrointestinal permeation. These processes depend on two main properties: solubility and permeability. Based on these characteristics, the Biopharmaceutical Classification System (BCS) was proposed as a tool to assist in biowaiver and bioavailability prediction of drugs. METHODS The purpose of the present study was to evaluate the permeability of lamivudine (3TC) and zidovudine (AZT) using a different ex vivo method in Franz cells. A segment of jejunum was inserted in a Franz cells apparatus, in order to assess drug permeability in the apical-basolateral (A-B) and basolateral-apical (B-A) directions. Each drug was added to the donor chamber, collected from the acceptor chamber and analyzed by HPLC. Fluorescein (FLU) and metoprolol (METO) were used as low and high permeability markers, respectively. RESULTS The apparent permeability (Papp) results for the A-B direction were: Papp FLU A-B=0.54×10(-4)cm·s(-1), Papp METO A-B=7.99×10(-4)cm·s(-1), Papp 3TC A-B=4.58×10(-4)cm·s(-1) and Papp AZT A-B=5.34×10(-4)cm·s(-1). For the B-A direction, the Papp results were: Papp FLU B-A=0.56×10(-4)cm·s(-1), Papp METO B-A=0.25×10(-4)cm·s(-1), Papp 3TC B-A=0.24×10(-4)cm·s(-1) and Papp AZT B-A=0.19×10(-4)cm·s(-1). DISCUSSION For the A-B direction, the Papp results of fluorescein and metoprolol show low and high permeability, respectively, indicating that the membranes were appropriate for permeability studies. For the A-B direction, the Papp results of 3TC and AZT suggest that these antiretroviral drugs have permeability values close to metoprolol. Nevertheless, for the B-A direction the Papp results do not suggest efflux mechanism for any of the drugs. Thereby, the different ex vivo methods using Franz cells can be successfully applied in drug permeability studies, in particular for drug biopharmaceutical classification.
Clinical Therapeutics | 2008
Cristina Helena dos Reis Serra; Eunice Emiko Mori Koono; Eunice Kazue Kano; Simone Grigoleto Schramm; Yara Popst Armando; Valentina Porta
BACKGROUND Zidovudine is a thymidine nucleoside reverse transcriptase inhibitor with activity against HIV type 1. Some (approximately 8) generic formulations of zidovudine are available in Brazil; however, based on a literature search, information concerning their bioavailability and pharmacokinetic properties in the Brazilian population has not been reported. OBJECTIVE The aim of this study was to compare the bioavailability and pharmacokinetic properties of 2 capsule formulations of zidovudine 100 mg in healthy Brazilian volunteers. METHODS This open-label, randomized, 2-way crossover study utilized a 1-week washout period between doses. Blood samples were collected for 8 hours after a single dose of zidovudine 100-mg test (Zidovudina, Fundação para o Remédio Popular, São Paulo, Brazil) or reference formulation (Retrovir, GlaxoSmithKline, Philadelphia, Pennsylvania). Plasma zidovudine concentrations were determined using a validated high-performance liquid chromatography method with ultraviolet detection at 265 nm. C(max), T(max), AUC(0-t), AUC(0-infinity), t(1/2), and the elimination constant (k(e)) were determined using noncompartmental analysis. The formulations were considered bioequivalent if the 90% CIs for C(max), AUC(0-t), and AUC(0-infinity) fell within the interval of 80% to 125%,the regulatory definition set by the US Food and Drug Administration (FDA). RESULTS Twenty-four healthy volunteers (12 males, 12 females; mean age, 27 years; weight, 60 kg; height, 167 cm) were enrolled and completed the study. The 90% CIs of the treatment ratios for the logarithmic transformed values of C(max), AUC(max)0-t, and AUC(0-infinity) were 80.0% to 113.6%, 93.9% to 109.7%, and 93.6% to 110.1%, respectively. The values for the test and reference formulations were within the FDA bioequivalence definition intervals of 80% to 125%. CONCLUSIONS In this small study in healthy subjects, no statistically significant differences in C(max), AUC(0-t), and AUC(0-infinity) were found between the test and reference formulations of zidovudine 100-mg capsules. The 90% CIs for the mean ratio values for the test and reference formulations of AUC(0-t), AUC(0-infinity), and C(max) indicated that the reported data were entirely within the bioequivalence acceptance range proposed by the FDA of 80% to 125% (using log-transformed data).
International Journal of Pharmaceutics | 2009
Yara Popst Armando; Simone Grigoleto Schramm; Marina de Freitas Silva; Eunice Kazue Kano; Eunice Emiko Mori Koono; Valentina Porta; Cristina Helena dos Reis Serra
The purpose of this study was to evaluate bioequivalence of two commercial 8 mg tablet formulations of ondansetrona available in the Brazilian market. In this study, a simple, rapid, sensitive and selective liquid chromatography-tandem mass spectrometry method is described for the determination of ondansetron in human plasma samples. The method was validated over a concentration range of 2.5-60 ng/ml and used in a bioequivalence trial between orally disintegrating and conventional tablet ondansetron formulations, to assess its usefulness in this kind of study. Vonau flash (Biolab Sanus Farmacêutica, Brazil, as test formulations) and Zofran (GlaxoSmithKline, Brazil, as reference formulation) were evaluated following a single 8 mg dose to 23 healthy volunteers of both genders. The dose was administered after an overnight fast according to a two-way crossover design. Bioequivalence between the products was determinated by calculating 90% confidence interval (90% CI) for the ratio of C(max), AUC(0-t) and AUC(0-infinity) values for the test and reference products, using logarithmically transformed data. The 90% confidence interval for the ratio of C(max) (87.5-103.8%), AUC(0-t) (89.3-107.2%) and AUC(0-infinity) (89.7-106.0%) values for the test and reference products is within the 80-125% interval, proposed by FDA, EMEA and ANVISA. It was concluded that two ondansetron formulations are bioequivalent in their rate and extent of absorption.
European Journal of Pharmaceutics and Biopharmaceutics | 2016
Thaisa Marinho Dezani; André Bersani Dezani; João Batista da Silva Junior; Cristina Helena dos Reis Serra
In recent years, the prediction of oral drug absorption in humans has been a challenge for researchers and many techniques for permeability studies have been developed for several purposes, including biowaiver processes. The Single-Pass Intestinal Perfusion (SPIP) method performed in rats can provide permeability results closest to in vivo condition. The purpose of the present study was to evaluate the intestinal permeability of the antiretroviral drugs lamivudine, stavudine and zidovudine using the SPIP method in rats and to predict their permeability (Peff,humans) and fraction absorbed (Fa) in humans. Metoprolol and fluorescein were used as marker compounds of high and low permeability, respectively. The effective permeability (Peff) results showed that stavudine and zidovudine have high permeability characteristics while lamivudine presented the lowest result. From Peff values obtained in rats, the Peff,humans and Fa were calculated. The use of SPIP in rats and calculations for absorption prediction in humans may indicate the transport mechanisms and/or pre-systemic metabolism involved on permeation processes of drugs, since this model is the closest to in vivo conditions.
Brazilian Journal of Pharmaceutical Sciences | 2013
André Bersani Dezani; Thaisa Marinho Pereira; Arthur Massabki Caffaro; Juliana Mazza Reis; Cristina Helena dos Reis Serra
A solubilidade e a taxa de dissolucao de farmacos sao de grande importância em estudos de pre-formulacao de formas farmaceuticas. A melhora na solubilidade permite que os farmacos sejam candidatos potenciais a bioisencao, podendo ser uma boa maneira para desenvolver formulacoes dose-eficientes. O comportamento de solubilidade da lamivudina, estavudina e zidovudina em solventes individuais (sob faixa de pH 1,2 a 7,5) foi estudado pelos metodos de solubilidade em equilibrio e dissolucao intrinseca. No estudo de solubilidade pelo metodo do equilibrio (metodo de agitacao de frascos), conhecidas quantidades do farmaco foram adicionadas em cada meio ate atingirem a saturacao e a mistura foi submetida a agitacao de 150 rpm por 72 horas a 37 oC. No ensaio de dissolucao intrinseca, conhecida quantidade de cada farmaco foi comprimida na matriz do aparato de Wood e submetida a dissolucao em cada meio com agitacao de 50 rpm a 37 oC. No metodo de solubilidade em equilibrio, a lamivudina e a zidovudina podem ser consideradas como farmacos altamente soluveis. Embora a estavudina apresente alta solubilidade nos meios pH 4,5, 6,8, 7,5 e agua, a determinacao da solubilidade em pH 1,2 nao foi possivel devido a problemas de estabilidade. Com relacao a dissolucao intrinseca, a lamivudina e a estavudina apresentaram alta velocidade de dissolucao. Considerando o valor limite apresentado por Yu e colaboradores (2004), todos os farmacos apresentaram caracteristicas de alta solubilidade no metodo de dissolucao intrinseca. Com base nos resultados obtidos, a dissolucao intrinseca parece ser superior para os estudos de solubilidade como um metodo alternativo para o proposito de classificacao biofarmaceutica.